The Efficacy of Ipilimumab for the Treatment of Melanoma
Antoni Ribas, MD, PhD, the director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, discusses the efficacy of ipilimumab for the treatment of melanoma.
Antoni Ribas, MD, PhD, the director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, discusses the efficacy of ipilimumab for the treatment of melanoma.
Ipilimumab blocks CTLA-4, which is a negative regulator of the immune system, and is important in the activation step of the immune system, Ribas explains.
When the immune system is being activated, CTLA-4 has its brake effect. If the brake effect is released, Ribas says, immune system cells may be able to target the cancer, but some immune cells may target other tissues, creating some risk.
Clinical Pearls
PD-1 is at the defector stage of the immune system, Ribas says, and releasing PD-1 is more likely to achieve a rapid response and be more targeted to the T cells that are cancer-specific.
- Ipilimumab blocks CTLA-4, a negative regulator of the immune system
- If the CTLA-4 brake effect is released, immune system cells may be able to target the cancer
- Releasing PD-1 is more likely to achieve a rapid response and be more targeted to the T cells that are cancer-specific
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
